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obstructive pulmonary disease in primary care?
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Background and aim: Early detection of COPD may reduce the future burden of the disease. 
We aimed to investigate whether prescreening with a COPD-6 screening device (measuring 
FEV
1
 and FEV
6
) facilitates early detection of COPD in primary care. 
Methods: In primary care, individuals at high risk of COPD (ie, age $35 years, relevant 
exposure, and at least one respiratory symptom) and no previous diagnosis of obstructive 
lung disease were examined with a COPD-6 screening device. In prioritized order, the cri-
teria for proceeding to confirmatory spirometry were FEV
1
/FEV
6
 ,0.7, FEV
1
 ,80%pred, 
or clinical suspicion of COPD regardless of test result (medical doctor’s [MD] decision). 
Based on spirometry, including bronchodilator (BD) reversibility test, individuals were clas-
sified as COPD (post-BD FEV
1
/FVC ,0.70), asthma (ΔFEV
1
 $0.50 L), or no obstructive 
lung disease.
Results: A total of 2,990 subjects (54% men, mean age 59 years, and mean 28 pack-years) were 
enrolled, of whom 949 (32%) proceeded from COPD-6 screening to confirmative spirometry 
based on the following criteria: 510 (54%) FEV
1
/FEV
6
 ,0.70, 382 (40%) FEV
1
 ,80%pred, and 
57 (6%) MD decision. Following confirmative spirometry, the 949 individuals were diagnosed 
as having COPD (51%), asthma (3%), and no obstructive lung disease (45%). COPD was diag-
nosed in 487 (16%) of the enrolled subjects in whom confirmative spirometry was performed 
in 69% based on FEV
1
/FEV
6
 ,0.7 and in 29% based on FEV
1
 #80%pred.
Conclusion: Prescreening with the COPD-6 device showed acceptable specificity for the 
selection of subjects for diagnostic spirometry and is likely to be a useful alternative to current 
practice in primary care.
Keywords: early COPD, diagnosis, spirometry, general practice
Introduction
Previous studies have shown that opportunistic screening in primary care enables early 
diagnosis of chronic obstructive pulmonary disease (COPD).1,2 However, in general, 
this practice is sparsely implemented. In population-based registry studies, only one 
third of subjects or less with newly diagnosed COPD had spirometry performed.3–6 
Furthermore, the requirement of conventional spirometry has been identified as a barrier 
to early diagnosis.7 Delayed diagnosis is a missed opportunity for early secondary 
prevention, most importantly smoking cessation, which could substantially alter the 
prognosis.8 The demand for screening of an increasing number of subjects has further 
stressed the need for a feasible procedure.
More than a decade ago, Buffels et al suggested that hand-held spirometers should 
be made available in primary care.9 FEV
6
 is a measure of forced expiratory volume in 
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6 seconds as opposed to a full forced vital capacity (FVC) 
maneuver. Studies have suggested FEV
1
/FEV
6
 measured by 
spirometry as a valid alternative to FEV
1
/FVC in screening 
a high-risk population for COPD.10,11 A meta-analysis based 
on 11 studies found a sensitivity of 0.89 (95% CI 0.83–0.93) 
and specificity of 0.98 (95% CI 0.95–0.99) for FEV
1
/FEV
6
 
in recognition of airway obstruction.12 Several studies have 
concluded that hand-held screening devices including the 
COPD-6 and PiKo-6 device are reliable in screening for 
airway obstruction and selecting subjects for further diag-
nostic workup.13–20 A recent meta-analysis concluded that 
the accuracy of FEV
1
/FEV
6
 measured by hand-held devices 
seems to be lower than spirometry, but sufficiently accurate 
to screen for airway obstruction.21
Existing studies of hand-held screening devices have 
called for studies conducted in a realistic screening setting. 
This study aimed to investigate whether prescreening with 
a COPD-6 device facilitates early detection of COPD in a 
primary care setting.
Materials and methods
Materials
Denmark has ~3,600 general practitioners (GPs), covering a 
population of 5.9 million. We aimed to include a representa-
tive sample, on a voluntary basis, comprising 180 GPs (cor-
responding to 5% of Danish GPs) from all over Denmark. 
Written information about the study as well as the invitation 
to participate was distributed to all interested GPs by the 
sponsor’s local representative.
More than 95% of Danish GPs own a spirometer, which 
was a requirement to participate in this study. Subjects were 
eligible for enrollment in the study provided they fulfilled 
the inclusion criteria based on recommendations from the 
Danish National Board of Health on opportunistic screening 
for COPD: age $35 years, smoker/ex-smoker or other risk 
exposures for COPD, at least one respiratory symptom 
(dyspnea, cough, wheeze, sputum, or recurrent respiratory 
tract infections)31 and had no previous diagnosis of obstruc-
tive lung disease or treatment with inhaler medication 
within the last 12 months. Exclusion criteria were absence 
of informed consent and inability to perform COPD-6- or 
spirometry procedure.
Methods
This multicenter study was conducted from March to 
December 2015. Based on the spirometry guidelines from 
the Danish Respiratory Society,32 participating GPs were 
educated in the functions of the COPD-6 (Vitalograph®, 
Buckingham, UK) and spirometry procedures. The COPD-6 
test was repeated three times with the highest values 
recorded. The device automatically detected blows of poor 
quality (start too slow, coughing, or ,3 seconds duration 
of blow). Spirometry was performed with at least three 
forced expiratory maneuvers (and at least two measure-
ments of FEV
1
 and FVC, differing by ,5%). European 
Community of Steel and Coal reference values for lung 
function were used.33
The bronchodilator (BD) reversibility tests were per-
formed with 0.4 mg inhaled salbutamol (or equivalent) 
followed by repeated spirometry 15 minutes later. All pro-
cedures were performed in general practice.
Subjects who fulfilled the criteria for inclusion were 
screened with the COPD-6 device (screening test) and 
proceeded to diagnostic spirometry with BD reversibility 
test, based on three criteria in prioritized order: 1) airway 
obstruction (FEV
1
/FEV
6
 ,0.70), 2) lung function impair-
ment, that is, FEV
1
 ,80%pred, or 3) medical doctor’s (MD) 
decision (FEV
1
/FEV
6
 close to 0.70 and sustained suspicion 
of COPD). The prioritized order meant that subjects pre-
senting with both airway obstruction and decreased lung 
function were categorized into airway obstruction. Based 
on the findings at the diagnostic spirometry, subjects were 
categorized as asthma (ΔFEV
1
 $0.50 L), COPD (post-BD 
FEV
1
/FVC ratio ,0.70), or no obstructive lung disease 
(remaining individuals).
Data handling and analysis
The aim was to identify at least 500 subjects with COPD and 
thereby allow for subgroup analyses. Recruitment of 180 GPs 
was estimated to be sufficient based on, 1) an expected inclu-
sion of at least 30 subjects by each GP, 2) a 15% prevalence 
of COPD, and 3) an expected dropout rate of 10%.
Data on age, sex, height, body weight, smoking status 
and/or other risk exposure, pack-years, respiratory symptoms 
(described above), severity of dyspnea (Medical Research 
Council scale),34 and results of COPD-6 (FEV
1
, FEV
6
) and 
spirometry (FEV
1
, FVC, post-BD FEV
1
, and FVC) were 
entered into a consolidated web-based database. Body mass 
index (BMI), FEV
1
/FEV
6
, and FEV
1
/FVC were automatically 
calculated and recorded.
Statistical analyses were performed by using IBM SPSS 
version 21 (IBM Corporation, Armonk, NY, USA). Analyses 
were limited to subjects with complete data. Continuous 
data were tested for normality and paired t-test was applied 
if applicable. For continuous non-normal distributed data, 
Mann–Whitney U test was used. Categorical data were 
analyzed by Pearson’s chi-squared test. A significance level 
of 0.05 was set in all analyses.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
17
8.
2 
on
 2
0-
Ja
n-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2325
Multicenter study of the COPD-6 screening device
ethics
The study was endorsed by the Danish College of General 
Practitioners. According to the European Federation of Phar-
maceutical Industries and Associations code and the Danish 
Association of the Pharmaceutical Industry, the present study 
was a non-drug, non-interventional study. Approval from 
the Danish Scientific Ethics Committee and The Danish 
Medicines Agency was not mandatory, but they were given 
all relevant study information. Data handling was approved 
by the Danish Data Protection Agency.
Results
Characteristics of enrolled subjects
A total of 149 GPs participated in the study, representing a 
nationwide sample of both large and small clinics. A total 
of 2,990 subjects were tested with the COPD-6 screening 
tool and had complete data (Figure 1). The study population 
had a mean age of 59 years (range 35–92 years), mean 28 
pack-years of smoking, 54% current smokers, and a COPD-6 
mean FEV
1
 of 2.6 L (88%pred) (Table 1).
Prevalence of COPD
According to the predefined criteria, confirmative spirometry 
was indicated in 949 cases (32% of study population) dis-
tributed as follows: 510 FEV
1
/FEV
6
 ,0.7 (with or without 
FEV
1
 ,80%pred), 382 FEV
1
 ,80%pred, and 57 MD deci-
sion. Of the 949 subjects tested with diagnostic spirometry, 
487 (51%) fulfilled the criteria for COPD (corresponding 
to 16% of the study population), 31 (3%) were categorized 
as having asthma (ΔFEV
1
 .0.5 L), and 431 (45%) as “no 
obstructive lung disease” (Figure 1).
The prevalence of COPD in subjects selected for diag-
nostic spirometry by criteria FEV
1
/FEV
6
 ,0.70 was 352/510 
(69%) and 110/382 (29%) based on the criteria FEV
1
 ,80% 
alone (Figures 2 and 3). The prevalence of airway obstruction 
at the COPD-6 test and at the pre- and post-BD spirometry 
are given in Table 2.
Criteria for confirmative spirometry
Applying the single criteria FEV
1
/FEV
6
 ,0.70 for further 
diagnostic work-up, 17% of the screened population would 
have proceeded to confirmative spirometry. However, com-
pared to the combined criteria used in the current study, 
a diagnosis of COPD would have been missed in 135 
(487–352) subjects, corresponding to 27% of all subjects 
diagnosed with COPD in the study. In total, 439 subjects had 
an FEV
1
/FEV
6
 $0.70 at the COPD-6 test, but proceeded to 
diagnostic spirometry based on FEV
1
 ,80%pred (382) or 
MD decision (57). Of these subjects, 137 had a post-BD ,0.7 
and 135 (31%) were diagnosed with COPD (Table 2).
For each subject diagnosed with COPD, six COPD-6 tests 
and two diagnostic spirometry procedures were performed.
Characteristics of subjects screened only 
with COPD-6 test
Subjects who did not meet criteria for diagnostic spirometry 
were in comparison to subjects diagnosed with COPD, signifi-
cantly younger, had less tobacco exposure, and had an overall 
Figure 1 COnsOrT diagram of enrolled subjects.
Notes: The following diagnostic criteria were applied: 1) COPD: post-bronchodilator (BD) FeV1/FVC ,0.7 and ,0.5 l post-BD increase in FeV1, 2) asthma: post-BD FeV1 
increase $0.5 L, and 3) no obstructive lung disease, that is, not fulfilling any of these criteria.
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV, forced expiratory volume; FVC, forced vital capacity; MD, medical doctor’s.
???????????????????????????
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?????????????????
???????????? ?????????????
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lower occurrence of respiratory symptoms with significantly 
less dyspnea, wheezing, and sputum (Table 1). As expected, 
the FEV
1
 was also on average significantly higher; 2.9 versus 
2.0 L (97% vs 69% predicted), respectively.
Characteristics of subjects with COPD 
compared to other diagnostic groups
Compared to subjects categorized as having asthma, subjects 
with COPD had significantly more pack-years and lower FEV
1
 
and FVC (Table 3). There were no significant differences in 
symptoms between the two groups, although occurrence of 
sputum tended to be higher in subjects with COPD.
Subjects with COPD, compared to subjects categorized as 
having no obstructive lung disease, had significant higher age, 
lower BMI, and higher number of pack-years and had signifi-
cantly higher occurrence of dyspnea and sputum (Table 3).
In the group with no obstructive lung disease, 215 (50%) 
subjects had FEV
1
.80%pred. For participants finally classified 
as having no obstructive lung disease, but having a confirmatory 
spirometry performed based on FEV
1
/FEV
6
 ratio ,0.70, 50% 
had a FEV
1
/FEV
6
 ratio close to 0.7 ($0.65). The mean increase 
in FEV
1
 at the BD reversibility test was 0.14 L (0.10).
Detailed spirometry data according to the three criteria 
for diagnostic spirometry are presented in Table 4.
Discussion
Main findings
The study demonstrates that, in a real-life setting, prescreening 
of high-risk subjects with the COPD-6 device followed by 
spirometry in selected cases can identify COPD in a high per-
centage of subjects (16%). Selection of subjects for confirma-
tive spirometry based on a single criteria FEV
1
/FEV
6
 ,0.70 
was found to be insufficient, and the sensitivity was markedly 
increased primarily by adding the criterion FEV
1
 ,80%pred, 
and to a lesser extent the criterion MD decision.
Screening with the COPD-6 device showed accept-
able specificity for the selection of subjects for diagnostic 
spirometry. 
Interpretation of findings in relation to 
previously published work
A COPD prevalence of 16% was comparable to findings (17%) 
reported from a previous study with similar study design, 
but screening performed only by conventional spirometry.2 
Table 1 Baseline characteristics of all enrolled subjects (n=2,990) 
and classification according to whether participants were only 
screened with COPD-6 test (n=2,041) or proceeded to confir­
mative spirometry (n=949)a
All 
(n=2,990)
COPD-6 
test only 
(n=2,041)
Confirmative 
spirometry 
(n=949)
P-valueb
sex, male 1,624 (54%) 1,119 (55%) 505 (53%) ns
age (years) 59 (11.7) 58 (11.7) 62 (11.0) ,0.001
BMI (kg/m2) 28 (5.7) 27 (5.6) 27 (5.9) ns
Pack-years 28 (20.0) 25 (18.8) 34 (22.2) ,0.001
FeV1 (l) 2.6 (0.8) 2.9 (0.73) 2.0 (0.64)
FeV1 %pred 88 (18.9) 97 (12.8) 69 (15.1)
FeV6 (l) 3.4 (0.97) 3.7 (0.92) 2.9 (0.86) ,0.001
symptoms
Cough 1,825 (61%) 1,232 (60%) 593 (63%) ns
Dyspnea 1,144 (38%) 724 (36%) 420 (44%) ,0.001
Wheezing 298 (10%) 151 (7%) 147 (16%) ,0.001
sputum 544 (18%) 327 (16%) 217 (23%) ,0.001
recurrent rTI 112 (4%) 65 (3%) 47 (5%) 0.018
MrCc
1 na na 176 (19%)
2 na na 234 (25%)
3 na na 83 (9%)
4 na na 13 (1%)
5 na na 2 (0.43%)
Notes: anumerical data presented as mean (sD) and categorical data as n (%). 
bsubjects screened only with the COPD-6 test compared to subjects who proceeded 
to confirmative spirometry. cMedical research Council dyspnea scale.
Abbreviations: BMI, body mass index; FeV, forced expiratory volume; MrC, 
Medical Research Council; NA, not applicable; NS, not significant; RTI, Respiratory 
tract infections.
Figure 2 Prevalence of final diagnosis, that is, COPD, asthma, or no obstructive 
lung disease, according to the three different criteria for proceeding to confirmative 
spirometry.
Notes: Criteria for, 1) COPD: post-bronchodilator (BD) FeV1/FVC ,0.7 and ΔFeV1 
,0.5 l at BD reversibility test; 2) asthma: ΔFeV1 $0.5 l at BD reversibility test; 
Non­OLD: not fulfilling criteria 1) or 2). MD decision: MD decision to perform 
confirmative spirometry based on suspicion of COPD and an FEV1/FVC ratio close 
to 0.7. subjects with both FeV1/FeV6 ratio ,0.7 and FeV1 ,80% were counted in the 
group “FeV1/FeV6 ratio ,0.7”.
Abbreviations: FeV, forced expi ratory volume; FVC, forced vital capacity; 
MD, medical doctor’s; OlD, obstructive lung disease.
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A post hoc analysis of data from that study showed that 
six screening spirometry and 1.4 confirmative spirometry 
procedures had to be performed per diagnosed subject with 
COPD.22 Compared to the current study, the COPD-6 device 
as expected did not reduce the total number of procedures 
(screening tests plus diagnostic tests), but worked as a replace-
ment for the conventional spirometry screening test.
Six other GP multicenter studies of screening with a 
COPD-6 device for early detection of COPD were identified. 
In accordance with the other studies, the vast majority of 
subjects in the current study had mild to moderate disease. 
For subjects with available data also on exacerbations, two-
thirds belonged to GOLD group A.
One study (Miravitlles et al) had to be disregarded as it is 
published only in Spanish.18 The two studies by Muller et al 
and Represas-Represas et al only included subjects if they 
had respiratory symptoms and exposure to tobacco smoke.14,19 
Muller et al19 included 17,856 subjects and found airway 
obstruction (FEV
1
/FEV
6
 ,0.7) in 17% of the subjects, 
and interestingly, a diagnosis of COPD was independently 
suspected by the MD three times more than indicated by the 
COPD-6 device. No data from confirmative spirometry was 
included in the study, thus, direct comparison with our study 
is not possible. A recent smaller study by Represas-Represas 
et al included a mixed cohort of 362 subjects from general 
practice, emergency services, and community pharmacies 
and found a COPD prevalence of 40% in the general practice 
cohort (n=167).23 The high prevalence of COPD most likely 
reflects a much higher tobacco exposure compared to the 
current study (75% active smokers, mean pack-years 39). 
An optimal cutoff of FEV
1
/FEV
6
 of 0.8 was proposed cor-
responding to a sensitivity of 92% and specificity of 53%.
Llordes et al included 407 subjects and found a COPD 
prevalence of 26%.24 The study was similar to our study with 
regard to smoking exposure and age, and no obvious explana-
tion for the difference in prevalence can be identified based 
on the available information. Different screening strategies 
including screening questionnaires and the COPD-6 device 
were tested, and the latter was found significantly superior 
with an FEV
1
/FEV
6
 cutoff of 0.78 (sensitivity 88% and 
specificity 72%).
Another multicenter study by Thorn et al including 
305 subjects found a COPD prevalence of 25%.17 The higher 
prevalence of COPD in that study was likely due to inclusion 
criteria with a minimum smoking exposure of $15 pack-
years. An FEV
1
/FEV
6
 cutoff of 0.73 was suggested, which 
corresponds to a sensitivity and specificity of 79% and 80%, 
Figure 3 Comparison of the FeV1/FeV6 ratio for subjects with airway obstruction (defined as FEV1/FeV6 ,0.70) at the COPD-6 test (A) (n=510) with the FeV1/FVC ratio 
at the subsequent post-BD spirometry (B).
Abbreviations: BD, bronchodilator; FeV, forced expiratory volume; FVC, forced vital capacity.
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Table 2 Prevalence of airway obstruction (FeV1/FVC ,0.70) at 
the COPD-6 test and at pre- and post-bronchodilator spirometry 
according to criteria for performing confirmative spirometry
Criteria for spirometry COPD-6 Spirometry 
pre-BDa
Spirometry 
post-BDb
(a) FeV1/FeV6 ,0.7 (n=510) 510 402 (79%) 368 (72%)
(B) FeV1 ,80%pred
c (n=382) na 139 (36%) 112 (29%)
(C) MDd (n=57) na 31 (54%) 25 (44%)
all (n=949) 510 572 (60%) 505 (53%)
Notes: aPre-BD values. bPost-BD values. csubjects with both FeV1/FeV6 ,0.7 and 
FeV1 ,80%pred included in a. 
dMD decision (continued clinical suspicion of COPD 
and FeV1/FeV6 close to 0.70).
Abbreviations: BD, bronchodilator; FeV, forced expiratory volume; FVC, forced 
vital capacity; MD, medical doctor’s; na, not applicable.
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respectively and at a cutoff of 0.7, the numbers were 53% 
and 90%, respectively. They concluded that the COPD-6 
device may reduce the number of unnecessary spirometry 
tests, and the results were similar to two other studies, in 
which an almost similar device (Piko-6, measuring FEV
1
/
FEV
6
) was validated for the prediction of COPD.15,16 None of 
the described studies accounted for the occurrence of asthma 
in the cohort. The present study also differed in the use of a 
combined criteria for confirmatory spirometry including both 
FEV
1
/FEV
6
 ratio ,0.7 and FEV
1
 ,80%pred.
While general screening of all individuals with smok-
ing exposure is not recommended, US Preventive Services 
Task Force (USPSTF) recently recommended screening 
of all exposed individuals with respiratory symptoms, 
which is in concordance with the latest recommendations 
from GOLD.25,26
Studies of spirometry and the correlation between FEV
1
/
FEV
6
 ratio and FEV
1
/FVC have suggested that the cutoff 
for airway obstruction when using FEV
6
 should be set at a 
significantly higher level.11,12,27,28 Accordingly studies of the 
COPD-6 device show that the best correlation to an FEV
1
/
FVC ratio of 0.7 is an FEV
1
/FEV
6
 ratio of 0.73–0.75.14,17,18 
However, our COPD-6 device was technically limited to a 
cutoff value for airway obstruction of 0.7. Thus, the combined 
Table 3 Characteristics of subjects diagnosed with COPD compared to subjects diagnosed with asthma and no obstructive lung 
disease (no OlD)a,b
COPD 
(n=487)
Asthma 
(n=31)
P-value  
(COPD vs asthma)
No OLD 
(n=431)
P-value  
(COPD vs no OLD)
sex, male 259 (53%) 22 (71%) 0.054 224 (52%) 0.714
age (years) 64 (10.5) 63 (12.5) 0.433 61 (11.2) ,0.001
BMI (kg/m2) 26 (5.1) 28 (5.8) 0.061 28 (6.5) ,0.001
Pack-years 37 (21.4) 27 (17.6) 0.005 30 (22.8) ,0.001
FeV1 (l) 2.0 (0.65) 3.0 (0.92) ,0.001 2.4 (0.73) ,0.001
FeV1 %pred 72 (16.9) 87 (21.1) ,0.001 80 (14.8) ,0.001
FVC (l) 3.3 (0.98) 4.5 (1.3) ,0.001 3.1 (0.93) ,0.001
FeV1/FVC 0.61 (0.08) 0.69 (0.14) 0.005 0.77 (0.06) ,0.001
ΔFeV1 (l) 0.08 (0.18) 0.74 (0.30) ,0.001 0.05 (0.18) ,0.001
symptoms
Cough 309 (63%) 18 (58%) 0.547 266 (62%) 0.588
Dyspnea 242 (50%) 15 (48%) 0.888 163 (38%) ,0.001
Wheezing 77 (16%) 6 (19%) 0.602 64 (15%) 0.687
sputum 129 (27%) 6 (19%) 0.380 82 (19%) 0.007
recurrent rTI 22 (5%) 1 (3%) 0.735 24 (6%) 0.466
MrCc
1 142 (34%) 8 (50%)  26 (6%)  
2 194 (47%) 7 (44%)  33 (8%)  
3 64 (15%) 7 (44%)  18 (4%)  
4 13 (3%) 0 (0%)  0 (0%)  
5 2 (0.5%) 0 (0%)  0 (0%)  
gOlD staged
I 152 (31%)
II 294 (60%)
III 38 (8%)
IV 3 (1%)
gOlD groupd,e
a 303 (62%)
B 57 (12%)
C 33 (7%)
D 22 (5%)
Notes: a1) Criteria for COPD: post-BD FeV1/FVC ,0.7 and ΔFeV1 ,0.5 l at BD reversibility test; 2) asthma: ΔFeV1 $0.5 L at BD reversibility test; No OLD: not fulfilling 
criteria 1) or 2). bnumerical data presented as mean (sD) and categorical data as n (%). cMedical research Council dyspnea scale. dglobal Initiative for Chronic Obstructive 
lung Disease. global strategy for Diagnosis, Management and Prevention of COPD; 2016. eIn 72 (15%) cases, the number of exacerbations was not recorded, thus the gOlD 
group could not be specified.
Abbreviations: BD, bronchodilator; BMI, body mass index; FeV, forced expiratory volume; FVC, forced vital capacity; MrC, Medical research Council; OlD, obstructive 
lung disease; rTI, respiratory tract infections.
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criterion for diagnostic spirometry was decided in order to 
compensate for the risk of insufficient sensitivity. Our results 
confirmed the issue by showing that although 439 diagnostic 
spirometry procedures could be spared, 27% of the subjects 
with COPD in the study would have been missed by the 
single criterion diagnostic algorithm. Accordingly, of the 
439 subjects with a normal COPD-6 test who proceeded to 
diagnostic spirometry based on the other two criteria, 31% 
was diagnosed with COPD.
GOLD recommends a simple and operational defini-
tion of airway obstruction in primary care (post-BD FEV
1
/
FVC ,0.70) and points out the risk of over-diagnosis in the 
elder- and under-diagnosis of the younger population.26 The 
MD decision criterion, by which the GP was allowed to per-
form diagnostic spirometry in subjects with FEV
1
/FEV
6
 close 
to 0.7, was in accordance with GOLD recommendations.
Significant BD reversibility is not uncommon in COPD.29 
In the current study, a strict definition of asthma (FEV
1
 
change .0.5 L) was chosen not only to exclude this group 
of subjects but also because some of these participants 
may have asthma–COPD overlap.30 As a result, the group 
of subjects diagnosed as having asthma was small (n=31). 
As expected, compared to the asthma group, the COPD group 
had significantly higher tobacco exposure, lower FEV
1
, and 
a trend toward a higher occurrence of sputum.
Subjects in the category “no obstructive lung disease” 
were overall a little younger with less tobacco exposure and 
less dyspnea and sputum. Half the subjects had normal FEV
1
 
at confirmative spirometry and the majority of the group 
were overweight or obese, most likely representing subjects 
without clinically significant lung disease, although some 
individuals may have asthma despite an only moderate, or 
no, response to a BD.
strengths and limitations of this study
The number of GPs enrolled was less than the planned 
180 GPs. Nevertheless, the aim of identifying 500 subjects 
with COPD was largely met (n=487). An acceptable num-
ber of potentially eligible subjects (n=233) were excluded 
for various reasons; further details are given in Figure 1. 
The study sample was large and included 149 GPs with a 
wide geographical representation from across the nation 
including large and small GP clinics. Thus, the results are 
very likely to be representative for GP clinics in general, at 
least in Denmark. The study group had a wide representa-
tion of age and an even distribution of sex. A large propor-
tion (more than half) of the study population were current 
smokers. With regard to the subjects who did not proceed 
to diagnostic spirometry, the characteristics seem to justify 
exclusion: younger, less tobacco exposure, less symptoms, 
and a mean FEV
1
 predicted of 97%. Furthermore, in order 
to improve the quality of the COPD-6 and spirometry test, 
experienced personnel visited the clinics and gave training 
in performing the procedures.
It limits the study that confirmative spirometry was 
not conducted on all included patients. Thus, the extent of 
false-negative COPD-6 procedures could not be examined. 
However, the number of COPD patients found in the study 
equals what was expected based on a prior spirometry 
screening study also in Danish primary care, which indicates 
few false negatives.22 Furthermore, the possibility of a 
false-negative COPD-6 test and missed COPD diagnosis 
was limited to subjects with mild disease (FEV
1
 .80%). 
Conducting both COPD-6 and conventional spirometry on all 
included patients would have conflicted with the secondary 
aim of the study to test whether the GPs found the COPD-6 
device feasible in everyday work. However, by leaving it out, 
a direct comparison of COPD-6 and conventional spirometry 
in COPD screening could not be done.
Implications for future research, policy, 
and practice
As the COPD-6 screening test seems to be less time consum-
ing and easier to perform, our results support the procedure 
as a favorable alternative which can facilitate the detection 
of COPD in primary care. The important aspect of the 
Table 4 Spirometry data grouped by selection criteria for confir­
mative spirometry
Criteria Aa 
(n=510)
Criteria Bb
(n=382)
Criteria Cc 
(n=57)
COPD-6
FeV1 (l) 1.9 (0.65) 2.06 (0.52) 2.72 (0.63)
FeV1 ,80%pred 65% (17.6) 70% (7.5) 91% (8.4)
FeV6 (l) 3.0 (0.93) 2.68 (0.67) 3.57 (0.87)
FeV1/FeV6 ratio 0.62 (0.08) 0.77 (0.05) 0.77 (0.06)
Confirmative spirometryd
FeV1 (l) 2.18 (0.76) 2.24 (0.64) 2.73 (0.68)
FeV1 ,80%pred 75% (19.2) 77% (13.4) 88% (15.4)
FVC (l) 3.39 (1.10) 3.06 (0.85) 3.81 (0.94)
FeV1/FVC ratio 0.64 (0.11) 0.73 (0.08) 0.72 (0.07)
ΔFeV1 (l) 0.11 (0.31) 0.07 (0.17) 0.03 (0.15)
ΔFeV1 .0.2 l and 12% 88 (17%) 40 (10.5%) 1 (1.8%)
Notes: aFeV1/FeV6 ,0.7. 
bFeV1 ,80% predicted. subjects with both FeV1/FeV6 ,0.7 
and FeV1 ,80% predicted are counted as a. 
cMedical Doctor’s decision (continued 
suspicion of COPD and FeV1/FeV6 ~0.7). dPost-bronchodilator values.
Abbreviations: FeV, forced expiratory volume; FVC, forced vital capacity.
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participating GPs’ experience with the COPD-6 screening 
tool is, therefore, currently being studied.
With focus on the COPD-6 device as a possible quick 
and handy screening tool, quality of the procedure must not 
be neglected. Standardization of the procedure is important 
to ensure reliability and reproducibility, as done in the 
present study.
Conclusion
The COPD-6 device seems to be a feasible alternative to 
conventional spirometry for early detection of COPD in 
general practice. Qualitative evaluation is necessary to fully 
assess the potential of the device in overcoming current 
barriers in screening for COPD in high-risk populations. 
Consensus on the exact criteria for performing confirmative 
spirometry including the optimal cutoff value for FEV
1
/FEV
6
 
ratio is needed.
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